Page last updated: 2024-11-08

exaltolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

exaltolide: synthetic musk odor; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID235414
CHEMBL ID3560504
CHEBI ID177420
SCHEMBL ID114310
MeSH IDM0057397

Synonyms (85)

Synonym
CHEBI:177420
cyclopentadecanolide
muskalactone
pentadecanolide
exaltolide
muskolactone
nsc36763
pentadecalactone
thibetolide
pentadecanoic acid, .xi.-lactone
1,15-pentadecanolide
nsc-36763
oxacyclohexadecan-2-one
106-02-5
15-hydroxypentadecanoic acid, lactone
2-pentadecalone
pentalide
15-hydroxypentadecanoic acid-epsilon-lactone
einecs 203-354-6
fema no. 2840
omega-pentadecalactone
pentadecanolactone
ai3-30956
pentadecanoic acid, 15-hydroxy-, xi-lactone
15-pentadecanolide
pentadecan-15-olide
14-oxytetradecane carbonic acid lactone
15-hydroxypentadecanoic acid lactone
nsc 36763
ccris 3682
omega-pentadecalactone, >=98%, fg
pentadecanolide, 98%
15-pentadecanolactone
P0985
A801360
NCGC00248297-01
NCGC00255022-01
tox21_301123
dtxsid6044359 ,
dtxcid4024359
cas-106-02-5
1-oxacyclohexadecan-2-one
AKOS015964064
ok17s3s98k ,
unii-ok17s3s98k
ec 203-354-6
1-oxa-2-cyclohexadecanone
FT-0624246
pentadecalactone [ii]
exaltolide [mi]
exaltex
cpe-215
pentadecalactone [inci]
.omega.-lactone
cyclopentadecalactone
.omega.-pentadecalactone [fhfi]
15-hydroxypentadeca-noic acid
omega-pentadecalactone [fcc]
.omega.-pentadecalactone
pentadecanoic acid, 15-hydroxy-, .xi.-lactone
1,15 -pentadecanolide
SCHEMBL114310
cyclopentadecanolactone
pentadecano-15-lactone
CHEMBL3560504
mfcd00039667
J-001527
pentadecanolide, puriss., >=99.0% (gc)
AC-9864
AS-57924
fema 2840
oxacyclohexadecan-2-one, 9ci, 8ci
pentadecanoic acid, 15-hydroxy-, laquo xiraquo -lactone
1, 15-pentadecanolide
pentadecanolide, analytical standard
15-oxypentadecenlactone
15-hydroxypentadecanoicacidlactone
F20373
Q9251595
STL560823
EN300-254580
36486-90-5
CS-0085751
HY-W035362
Z57959539
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
macrolideA macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency16.26520.000714.592883.7951AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
thyroid stimulating hormone receptorHomo sapiens (human)Potency68.58960.001628.015177.1139AID1259395
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's0 (0.00)18.2507
2000's1 (6.25)29.6817
2010's10 (62.50)24.3611
2020's4 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.14 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.87 (4.65)
Search Engine Demand Index59.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]